Phathom Pharmaceuticals, Inc.
PHAT
$10.58
-$0.21-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 216.93% | 460.30% | 1,049.81% | 3,055.71% | 8,001.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 216.93% | 460.30% | 1,049.81% | 3,055.71% | 8,001.47% |
| Cost of Revenue | 183.46% | 333.92% | 658.41% | 1,800.67% | 4,674.25% |
| Gross Profit | 222.57% | 485.20% | 1,146.76% | 3,427.64% | 9,080.39% |
| SG&A Expenses | -3.77% | 13.67% | 52.36% | 100.28% | 146.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.71% | 14.79% | 45.80% | 75.53% | 98.05% |
| Operating Income | 42.34% | 25.86% | -6.41% | -38.22% | -65.84% |
| Income Before Tax | 33.82% | 19.12% | -11.12% | -40.21% | -65.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.82% | 19.12% | -11.12% | -40.21% | -65.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.82% | 19.12% | -11.12% | -40.21% | -65.84% |
| EBIT | 42.34% | 25.86% | -6.41% | -38.22% | -65.84% |
| EBITDA | 42.40% | 25.90% | -6.43% | -38.28% | -65.93% |
| EPS Basic | 43.00% | 33.04% | 7.85% | -18.80% | -37.69% |
| Normalized Basic EPS | 43.00% | 33.03% | 7.85% | -18.80% | -37.69% |
| EPS Diluted | 43.00% | 33.04% | 7.85% | -18.80% | -37.69% |
| Normalized Diluted EPS | 43.00% | 33.03% | 7.85% | -18.80% | -37.69% |
| Average Basic Shares Outstanding | 15.46% | 20.94% | 21.26% | 20.48% | 23.26% |
| Average Diluted Shares Outstanding | 15.46% | 20.94% | 21.26% | 20.48% | 23.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |